Novartis Sees Differentiated Process for Biogenerics
Such a regulatory scheme would allow fast-track approval of relatively simple biotech generics but require tough testing of more complicated remedies, Chairman and Chief Executive Daniel Vasella told Reuters.
Up until now, biotech drugs have been sheltered from competition because of the slow approval process for biotech generics.
Vasella's comments comes on the heels of a report in the...
To view the full article, register now.